Experimental stroke drug RNS60 passes early safety check in small trial
NCT ID NCT04693715
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested the safety of an experimental drug called RNS60 in 83 people having a severe stroke caused by a large blood clot. Participants received either RNS60 or a placebo as a 48-hour infusion, starting within 30 minutes of consent. The main goal was to check for serious side effects and survival at 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RNS60 injection solution
What this could lead to
If safe and effective, RNS60 could improve recovery after severe stroke by protecting brain cells during treatment.
What could go wrong
This is an early Phase 2 safety trial with only 83 participants, so results may not confirm benefit. The drug is still experimental and not yet proven to work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE, ISCHEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chattanooga Center for Neurologic Research
Chattanooga, Tennessee, 37404, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States